MindMed Begins Study On LSD Neutralizer Technology

MindMed (NEO: MMED) this morning announced that it has begun a study on what it refers to as “LSD neutralizer technology.” The tech is intended to stop the effects of an LSD trip while a patient is undergoing a therapy session.

The study is being conducted with the University Hospital Basel’s Liechti Lab via a phase one trial, which will evaluate the effect of ketanserin on the response to LSD after LSD administration. The project is associated with the firms LSD therapy studies referred to as Project Lucy, with the company looking to improve the therapy session with additional features to create a better patient experience.

Expected to be completed by year end, the company is effectively looking to evaluate the compound for use as an “emergency-off” switch for psychedelic assisted therapies. The tech, if successful, is ideal for when a “bad trip” occurs for the patient, or the session is not going as intended.

The study will work under the premise that the administration of 40mg of ketanserin one hour after taking LSD will significantly shorten and reduce the effects of LSD, when compared to LSD alone and a placebo. The compound is currently marketed as an antihypertensive agent.

Mindmed last traded at $5.31 on the NEO.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Snowline Gold: The Multi Billion Dollar Valley PEA

Euro Sun: Rovina Copper-Gold Project Secures Some Major Funding

Arizona Metals: The Disappointing Kay Mine Resource Estimate

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

MindMed Reveals Favorable Results From Phase 1 Trial Of Drug Candidate For Opioid Withdrawal Treatment

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the topline results...

Thursday, May 19, 2022, 09:29:00 AM

MindMed Adds MDMA To R&D Pipeline

Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching...

Wednesday, May 27, 2020, 09:00:04 AM

MindMed Starts Clinical Trial For Intravenous DMT

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the start of...

Wednesday, July 28, 2021, 10:22:00 AM

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Friday, September 17, 2021, 03:23:00 PM